3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
8
Terminated
3
Active not recruiting
3
Recruiting
2
Unknown
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
12
Triple Negative Breast Neoplasms
8
HER2-negative Breast Cancer
2
Neoplasm Metastasis
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
HR Positive HER2 Negative Advanced Breast Cancer
1
Breast Neoplasms, Male
1
Breast Cancer Organoids
1
Brain Neoplasms
1
Interventions
Fluorouracil
18
Oxaliplatin
17
Capecitabine
16
Leucovorin
13
Cisplatin
12
Gemcitabine
11
Drug Therapy
11
Irinotecan
10
Radiosurgery
9
Cetuximab
9
Bevacizumab
9
pembrolizumab
8
Docetaxel
8
Everolimus
7
spartalizumab
6
Sunitinib
6
Radiotherapy
6
Paclitaxel
6
Neoadjuvant Therapy
6
Cyclophosphamide
6
Trastuzumab
5
S 1 (combination)
5
Nivolumab
5
Immunotherapy
5
Immune Checkpoint Inhibitors
5
Chemotherapy, Adjuvant
5
Carboplatin
5
palbociclib
4
manganese chloride
4
Surgical Procedures, Operative
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Neoplasm Metastasis
×
eribulin
×
Clear all
NCT02175446
2016-06-15
GIM11-BERGI
Consorzio Oncotech
Phase 2
Unknown
61 enrolled